AI Article Synopsis

  • - This study compared the effectiveness of two bivalent COVID-19 vaccines (mRNA-1273.222 and BNT162b2 Bivalent) in preventing serious COVID-19 outcomes in adults with pre-existing health conditions.
  • - Researchers used a large dataset and methods like inverse probability weighting to analyze over 1.9 million adults who received these vaccines and tracked COVID-related hospitalizations and outpatient visits up to May 2023.
  • - Results showed that mRNA-1273.222 had a higher relative vaccine effectiveness—10.9% for hospitalizations and 3.2% for outpatient encounters—especially among individuals with conditions like diabetes and cardiovascular diseases.

Article Abstract

Background/objectives: This retrospective cohort study evaluated the relative vaccine effectiveness (rVE) of two bivalent (original/Omicron BA.4/BA.5) vaccines mRNA-1273.222 versus the BNT162b2 Bivalent in preventing COVID-19-related outcomes in adults with underlying medical conditions associated with increased risk for severe COVID-19.

Methods: In a linked electronic health record/claims dataset, US adults (≥18 years) with ≥1 underlying medical condition of interest who received either the bivalent vaccine between 31 August 2022 and 28 February 2023 were identified. The inverse probability of treatment weighting was used to adjust for cohort differences. Cohorts were followed up for COVID-19-related hospitalizations and outpatient encounters until 31 May 2023. Hazard ratios and rVEs were estimated using Cox regression. Subgroup analyses were performed on individuals with pre-specified comorbid conditions.

Results: 757,572 mRNA-1273.222 and 1,204,975 BNT162b2 Bivalent recipients were identified. The adjusted rVE over a median follow-up of 198 days was 10.9% (6.2%-15.2%) against COVID-19-related hospitalization and 3.2% (1.7%-4.7%) against COVID-19-related outpatient encounters. rVE estimates for COVID-19 hospitalizations among subgroups with comorbid conditions were as follows: diabetes 15.1% (8.7%-21.0%), cerebro- and cardiovascular disease 14.7% (9.0%-20.1%), chronic lung disease 11.9% (5.1%-18.2%), immunocompromised 15.0% (7.2%-22.2%), chronic kidney disease 8.4% (0.5%-15.7%).

Conclusions: Overall, among adults with underlying medical conditions, mRNA-1273.222 was more effective than BNT162b2 Bivalent, especially in preventing COVID-19-related hospitalizations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511346PMC
http://dx.doi.org/10.3390/vaccines12101107DOI Listing

Publication Analysis

Top Keywords

bnt162b2 bivalent
16
underlying medical
16
adults underlying
12
medical conditions
12
bivalent original/omicron
8
original/omicron ba4/ba5
8
vaccines mrna-1273222
8
bivalent preventing
8
preventing covid-19-related
8
covid-19-related hospitalizations
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!